Pfizer (PFE) has announced that its drug Litfulo met primary goals in two large late-stage studies for nonsegmental vitiligo, the most common form of the skin-pigmentation disorder.
Both studies showed significantly more patients on the drug achieved at least a 75% improvement in facial repigmentation compared with those given placebo after 52 weeks.
Patients taking Litfulo also demonstrated at least a 50% improvement in total-body repigmentation over the same period, strengthening the case for regulatory submission.
Pfizer said it plans to submit the data to health regulators globally as it seeks approval for the treatment in adults living with nonsegmental vitiligo.
Litfulo, known generically as ritlecitinib, is currently being explored in the Phase III Tranquillo study, which has been central to building the clinical evidence package for this indication.
The vitiligo treatment space is becoming increasingly competitive, with several major pharmaceutical companies racing to bring new oral therapies to patients who have historically had limited options.
AbbVie (ABBV) submitted regulatory applications to both the FDA and EMA in February 2026 for upadacitinib, sold under the brand name Rinvoq, targeting adults and adolescents with nonsegmental vitiligo.
Incyte is also mounting a significant challenge in the space, with the company planning to use its latest Phase 3 data to support its own vitiligo approval push to regulators, currently scheduled for the first half of 2027.
The three-way competition signals growing pharmaceutical confidence in the commercial potential of the vitiligo market, which has long been considered underserved by existing treatments.
Nonsegmental vitiligo affects millions of people worldwide, causing patches of skin to lose their pigmentation, and the arrival of effective oral therapies could represent a meaningful shift in how the condition is managed clinically.
Pfizer’s move into vitiligo also represents a broader strategy for Litfulo, which already holds approval for alopecia areata, as the company looks to expand the drug’s reach across autoimmune and inflammatory skin conditions.
Regulatory decisions on these competing drugs will be closely watched by dermatologists, patients, and investors alike as the market for advanced vitiligo treatments begins to take shape.